Biosimilars – a Different type of aHUS Drug
Biosimilar drugs are having an increased presence in conversations about the aHUS therapeutic drug landscape. Here's why they're of interest.
aHUS Drug Candidates – the 2022 Landscape
What’s new in 2022 regarding expansion in atypical HUS knowledge, and advancements for investigational drugs which may have potential as new…
2020 Atypical Drug Discovery Review, released by the aHUS Alliance
2020 overview of atypical HUS therapeutic drug development, by the aHUS Alliance
Small Molecule Factor D Inhibitors – Right for aHUS?
Out of more than 7000 rare diseases, only an estimated 5% have an approved treatment or therapy (Rare Disease Day, FAQs).…
Breaking Down Barriers in aHUS Clinical Trials
Break down in communication flows and fragmented outreach have built barriers for research and clinical trial enrollment regarding advancing new options for those with the rare disease atypical HUS (aHUS, or hemolytic uremic syndrome). The aHUS Alliance looks at current challenges, and potential pathways to explore and engage.